Metpath-G 1 Tablet is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea derivative, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, contributing to enhanced glycemic control. This dual-action formulation is particularly beneficial for patients inadequately controlled on diet, exercise, and monotherapy with either agent alone. Metpath-G 1 Tablet should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, diarrhea, and abdominal discomfort. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as well as in those with known hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Metpath-G 1 Tablet offers an effective and convenient therapeutic option for optimizing glycemic control in type 2 diabetes, reducing the risk of microvascular and macrovascular complications when used as part of a comprehensive diabetes management plan including diet and exercise.